Explore Ankura's latest insights spanning pharmaceutical manufacturing reshoring challenges, cybersecurity threats targeting crypto users, construction joint venture governance failures, and Saudi Arabian debt restructuring. Discover how industries are navigating capital deployment constraints, regulatory complexity, and emerging risks across healthcare, banking, data centers, and technology sectors.
Pharma Reshoring and the New Category of Execution Risk
Pharma’s manufacturing reshoring ambitions have outpaced the industry’s ability to execute them. Companies are launching multiple, concurrent capital programs on a scale and timeline the industry has never experienced — without a proven playbook. The result is a growing tension between aggressive growth targets and the realities of regulatory complexity, supply-chain constraints, and limited experienced talent.
A wave of pharmaceutical manufacturing is returning to the U.S. after decades of offshoring practices born from cost-cutting measures and tax incentives. While the U.S. labor market remains costly, policy pressure, tariff exposure, geopolitical risk, and hard lessons about supply-chain fragility have converged into a single strategic conclusion across the drug industry: Critical medicines production needs to sit on or near U.S. soil. The scale of announced domestic investment is striking — the White House’s public
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
View source